Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 90, Issue 5, Pages 732-736Publisher
WILEY
DOI: 10.1038/clpt.2011.207
Keywords
-
Categories
Ask authors/readers for more resources
Blinding, or masking, is a crucial method for reducing bias in randomized clinical trials. In this paper, we review important methodological aspects of blinding, emphasizing terminology, reporting, bias mechanisms, empirical evidence, and the risk of unblinding. Theoretical considerations and empirical analyses support the blinding of patients, health-care providers, and outcome assessors as to the trial intervention to which patients have been allocated. We encourage extensive pretrial testing of blinding procedures and explicit reporting of who was in the blinded condition and the methods used to ensure blinding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available